Our Organization Insilico Medicine, Inc.
Our Organization Insilico Medicine, Inc.
Lavender Swirl Background

Insilico Medicine, Inc.

Data Science holds the promise for faster drug discovery, development and testing. Insilico will deliver on that promise.

Insilico Medicine, Inc. is a Johns Hopkins-based company using artificial intelligence (AI) and deep learning for drug discovery to produce compounds targeted to the diseases of aging.

Insilico will lead by relentlessly innovating, publishing proofs of concept and delivering AI software that deploys the latest technology. A key concept to Insilico’s approach is ruthless internal competition, where different models compete against each other to rapidly prove which is superior and offers greater results.

Insilico Medicine’s “end-to-end” AI platform for drug discovery covers target identification & validation, compound generation and patient selection.

Juvenescence and Insilico have created a joint venture, Generait Pharmaceuticals, that has the first right to five compounds per year from Insilico. Insilico’s capabilities can be leveraged by the Juvenescence partners to speed hit-to-lead discovery.

In the News

Insilico Medicine

Insilico Enters Into Research Collaboration with Pfizer Inc.

Insilico Medicine, a Juvenescence partner, enters into research collaboration with Pfizer Inc. to utilize Insilico’s machine learning technology to identify evidence for potential therapeutic targets implicated in a variety of diseases.

January 13, 2020

Read More
Insilico Medicine

Nature Biotech: ‘Deep learning enables rapid identification of potent DDR1 kinase inhibitors’

Insilico Medicine, a Juvenescence partner, recently highlighted their ability to use deep learning for de novo small-molecule design in Nature Biotech.

September 20, 2019

Read More
Insilico Medicine

Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners

Insilico Medicine, a next generation AI technology and Juvenescence partner, completes $37 million Series B funding that will be used to commercialize the validated generative chemistry and target identification technology.

September 9, 2019

Read More

Contact Us

We are here to help answer any questions you might have.